Biocon Biologics has announced a new agreement with Civica Inc., “to expand patient access and affordability to insulin aspart in the US.” India-based Biocon Biologics does not currently have an approved insulin aspart biosimilar in the US, but it is approved in Canada. The company is pursuing its own insulin aspart biosimilar in the US, … Continue reading Biocon Biologics Agrees to Supply Civica With Materials to Bring Another Biosimilar Insulin Aspart to Market